Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more
Shandong Realcan Pharmaceutical Co Ltd (002589) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.003x
Based on the latest financial reports, Shandong Realcan Pharmaceutical Co Ltd (002589) has a cash flow conversion efficiency ratio of -0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-15.60 Million) by net assets (CN¥5.45 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Realcan Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shandong Realcan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Realcan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHINA RISUN GROUP HD-10
F:45Y
|
N/A |
|
Three's Company Media Group Co Ltd
SHG:605168
|
-0.021x |
|
Plejd AB
ST:PLEJD
|
0.056x |
|
0CIH
LSE:0CIH
|
N/A |
|
LAMDA Development S.A.
AT:LAMDA
|
-0.046x |
|
Bank Tabungan Negara Persero
JK:BBTN
|
0.672x |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
-0.002x |
|
Shenzhen Sunxing Light Alloys
SHG:603978
|
-0.074x |
Annual Cash Flow Conversion Efficiency for Shandong Realcan Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.69 Billion | CN¥160.44 Million | 0.028x | +92.59% |
| 2023-12-31 | CN¥5.64 Billion | CN¥82.47 Million | 0.015x | -83.91% |
| 2022-12-31 | CN¥5.75 Billion | CN¥523.07 Million | 0.091x | +99.01% |
| 2021-12-31 | CN¥9.69 Billion | CN¥442.95 Million | 0.046x | +6.19% |
| 2020-12-31 | CN¥9.64 Billion | CN¥414.96 Million | 0.043x | -78.93% |
| 2019-12-31 | CN¥10.25 Billion | CN¥2.09 Billion | 0.204x | +1245.34% |
| 2018-12-31 | CN¥11.31 Billion | CN¥-201.66 Million | -0.018x | +92.88% |
| 2017-12-31 | CN¥9.67 Billion | CN¥-2.42 Billion | -0.250x | -6.78% |
| 2016-12-31 | CN¥7.50 Billion | CN¥-1.76 Billion | -0.234x | -71.19% |
| 2015-12-31 | CN¥3.40 Billion | CN¥-466.26 Million | -0.137x | -52.79% |
| 2014-12-31 | CN¥1.83 Billion | CN¥-163.62 Million | -0.090x | +46.11% |
| 2013-12-31 | CN¥1.65 Billion | CN¥-274.46 Million | -0.166x | +10.61% |
| 2012-12-31 | CN¥916.39 Million | CN¥-170.52 Million | -0.186x | +67.99% |
| 2011-12-31 | CN¥817.11 Million | CN¥-475.03 Million | -0.581x | -343.92% |
| 2010-12-31 | CN¥296.03 Million | CN¥70.56 Million | 0.238x | -9.07% |
| 2009-12-31 | CN¥234.18 Million | CN¥61.38 Million | 0.262x | +158.80% |
| 2008-12-31 | CN¥111.89 Million | CN¥-49.88 Million | -0.446x | -- |